Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy
Psychedelic Medicine – May 08, 2024
Source: OpenAlex
Summary
Establishing clear boundaries for therapeutic touch is critical in psilocybin-assisted therapy, a growing area in medicine and psychology. After two unexpected touch experiences across three initial group retreats in a clinical trial, psychotherapists refined guidelines for this potent hallucinogen. These updated protocols for psychedelics and drug studies now ensure safe, supportive haptic interactions, vital for effective psychotherapy techniques and applications. Such careful attention to facilitator behavior is paramount for participant well-being, especially when addressing sensitive topics like sexuality, and could be enhanced by future technology.
Abstract
For a new clinical trial testing a group retreat-based format of psilocybin-assisted therapy, our research team created an initial set of practice guidelines that aimed to describe facilitator use of touch in a way that is ethical, supportive, and minimizes harm. In our first three retreats, however, we had two unexpected experiences with touch that led us to iterate our initial guidelines into a new version of guidelines. In this Technical Report, we describe our evolving guidelines specifying acceptable practices for facilitator use of touch to ensure a safe, supportive, and therapeutic participant experience. Our primary goal with these guidelines is to create a haptic experience during the psilocybin session that reinforces the participants' sense of safety and supports their own experience during the psilocybin session. Our secondary goal is to allow the facilitator team to notice and maintain therapeutic boundaries and to respond to participant experiences with empathy and openness in the context of those boundaries (Clinical Trials No: NCT05847686).